Search hospitals

>

Quebec

>

MONTREAL

Maisonneuve-Rosemont Hospital

Claim this profile

MONTREAL, Quebec H1T 2M4

Global Leader in Breast Cancer

Global Leader in Cancer

Conducts research for Acute Myeloid Leukemia

Conducts research for Leukemia

Conducts research for Colorectal Cancer

317 reported clinical trials

26 medical researchers

Photo of Maisonneuve-Rosemont Hospital in MONTREALPhoto of Maisonneuve-Rosemont Hospital in MONTREALPhoto of Maisonneuve-Rosemont Hospital in MONTREAL

Summary

Maisonneuve-Rosemont Hospital is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Cancer, Acute Myeloid Leukemia, Leukemia, Colorectal Cancer and other specialties. Maisonneuve-Rosemont Hospital is involved with conducting 317 clinical trials across 475 conditions. There are 26 research doctors associated with this hospital, such as Michael Yassa, Jonathan Noujaim, Dr. Mai-Kim Gervais, and Veronique Brulotte, MD, MSc.

Area of expertise

1

Breast Cancer

Global Leader

Maisonneuve-Rosemont Hospital has run 29 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
HER2 positive
2

Cancer

Global Leader

Maisonneuve-Rosemont Hospital has run 28 trials for Cancer. Some of their research focus areas include:

Stage IV
NPM1-m positive
Stage II

Top PIs

Clinical Trials running at Maisonneuve-Rosemont Hospital

Acute Myeloid Leukemia

Prostate Cancer

Breast Cancer

Cancer

Ovarian Cancer

Acute Lymphoblastic Leukemia

Leukemia

Acute Leukemia

Chronic Renal Failure

Cardiovascular Disease

Image of trial facility.

Combination Therapies

for Acute Myeloid Leukemia

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the growth of cancer cells. Daunorubicin is a drug that blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Azacitidine is a drug that interacts with DNA to activate tumor-suppressing genes, resulting in an anti-tumor effect. Adding venetoclax to cytarabine and daunorubicin, and adding venetoclax to azacitidine, may work better than the usual treatment of cytarabine with daunorubicin alone. To decide if they are better, the study doctors are looking to see if venetoclax increases the rate of elimination of AML in participants by 20% or more compared to the usual approach.

Recruiting

1 award

Phase 2

6 criteria

Image of trial facility.

JNJ-75276617

for Acute Leukemia

This trial tests JNJ-75276617, an oral drug designed to block a protein interaction that helps leukemia cells grow. It targets patients with specific genetic types of AML or ALL. By stopping these proteins from working together, the drug aims to slow down or stop cancer cell growth.

Recruiting

1 award

Phase 1 & 2

6 criteria

Image of trial facility.

Ziftomenib

for Relapsed/Refractory Acute Myeloid Leukemia

This trial is testing ziftomenib, a new drug, in patients with difficult-to-treat acute myeloid leukemia (AML). The drug works by blocking a protein interaction that cancer cells need to grow.

Recruiting

1 award

Phase 1 & 2

9 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Maisonneuve-Rosemont Hospital?

Where is Maisonneuve-Rosemont Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does Maisonneuve-Rosemont Hospital accept?

What awards or recognition has Maisonneuve-Rosemont Hospital received?